The Kislinger Laboratory is located at the Princess Margaret Cancer Research Tower of the Princess Margaret Cancer Centre, the largest oncology treatment and research facility in Canada. The major goal of our lab is to apply proteomics technologies to cancer and cardiovascular research. Our research interests include technology development, using the latest generation of mass spectrometry instrumentation, basic cell biology and translational cancer research.
In-depth proteomics of ovarian cancer ascites: combining shotgun proteomics and selected reaction monitoring mass spectrometry.
J Proteome Res. 2011 May 6;10(5):2286-99
Identification of novel ryanodine receptor 1 (RyR1) protein interaction with calcium homeostasis endoplasmic reticulum protein (CHERP).
J Biol Chem. 2011 May 13;286(19):17060-8
Identification of an FHL1 protein complex containing ACTN1, ACTN4, and PDLIM1 using affinity purifications and MS-based protein-protein interaction analysis.
Mol Biosyst. 2011 Apr;7(4):1185-96
Targeted proteomics by selected reaction monitoring mass spectrometry: applications to systems biology and biomarker discovery.
Mol Biosyst. 2011 Feb;7(2):292-303
Constitutively active calcineurin induces cardiac endoplasmic reticulum stress and protects against apoptosis that is mediated by alpha-crystallin-B.
Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18481-6
J Cell Mol Med. 2010 Dec;14(12):2702-20
Primary tumor xenografts of human lung adeno and squamous cell carcinoma express distinct proteomic signatures.
J Proteome Res. 2011 Jan 7;10(1):161-74
System-level analysis of neuroblastoma tumor-initiating cells implicates AURKB as a novel drug target for neuroblastoma.
Clin Cancer Res. 2010 Sep 15;16(18):4572-82
Endoplasmic reticulum protein targeting of phospholamban: a common role for an N-terminal di-arginine motif in ER retention?
PLoS One. 2010;5(7):e11496
PLoS One. 2010;5(5):e10854
Senior Scientist, Princess Margaret Cancer Centre